[Form 4] Acrivon Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Acrivon Therapeutics insider transaction summary: Eric Devroe, Chief Operating Officer of Acrivon Therapeutics, reported a single Form 4 transaction. On 08/14/2025 the reporting person had 613 shares withheld at a price of $1.39 per share as a result of tax withholding tied to the vesting of restricted stock units. After this withholding disposition, the reporting person beneficially owns 65,921 shares of Acrivon common stock, held directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to satisfy mandatory tax obligations and includes a Power of Attorney exhibit.

Insights

Financial Analyst

TL;DR: Routine tax-withholding disposition from RSU vesting; not a directional trade signal.

The Form 4 shows 613 shares were withheld at $1.39 to cover taxes on vested restricted stock units, leaving 65,921 shares beneficially owned directly by the COO. This type of entry is typically administrative and does not indicate a purchase or voluntary sale by the insider. There is no change in indirect holdings or new derivative activity disclosed. For investors, the filing clarifies executive holdings but provides no material information about company operations or outlook.

Corporate Governance Expert

TL;DR: Disclosure complies with Section 16 reporting; transaction appears procedural.

The submission identifies the reporting person as the Chief Operating Officer and provides required detail: transaction date (08/14/2025), code (F) indicating tax withholding, price ($1.39), and resulting direct ownership (65,921 shares). The presence of Exhibit 24 (Power of Attorney) and a signature by an attorney-in-fact on 08/18/2025 align with standard practice. This filing raises no governance concerns and reflects routine compliance activity rather than a governance event.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Devroe Eric

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2025		F(1)		613	D	$1.39	65,921	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Adam D. Levy, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What change did ACRV insider Eric Devroe report on Form 4?

The filing reports 613 shares were withheld to satisfy tax withholding upon RSU vesting; no open-market sale or purchase was reported.

How many ACRV shares does the reporting person own after the transaction?

After the withholding disposition the reporting person beneficially owns 65,921 shares of Acrivon common stock, held directly.

What was the price per share recorded for the withheld shares?

The transaction price recorded for the withheld shares was $1.39 per share.

When was the transaction and when was the Form 4 signed?

The transaction date is 08/14/2025 and the Form 4 was signed by an attorney-in-fact on 08/18/2025.

What does transaction code 'F' mean on this Form 4?

Code F is used here to indicate shares were withheld by the issuer to satisfy tax withholding obligations upon RSU vesting, per the filing.